

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	). F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/727,017		12/02/2003	Marcel Bally	532552001200	4423	
25225	7590	10/05/2006		EXAM	EXAMINER	
	ON & FO	ERSTER LLP	SWARTZ, RODNEY P			
SUITE 10	<b></b>	DidVE	ART UNIT	PAPER NUMBER		
SAN DIE	GO, CA 9	2130-2040	1645	_ <del></del>		
			DATE MAIL ED. 10/05/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Арр	lication No.	Applicant(s)	Applicant(s)				
Office Action Summary			27,017	BALLY ET AL.	BALLY ET AL.				
			miner	Art Unit					
		Rodi	ney P. Swartz, Ph.D.	1645					
Period fo	The MAILING DATE of this communicat r Reply	ion appears o	on the cover sheet with t	he correspondence ac	ddress				
WHIC - Exten after: - If NO - Failur Any n	ORTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE MAIL sions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communic period for reply is specified above, the maximum statutor to reply within the set or extended period for reply will, eply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE C 7 CFR 1.136(a). In ation. ry period will apply by statute, cause to	OF THIS COMMUNICAT in no event, however, may a reply and will expire SIX (6) MONTHS the application to become ABAND	TION. be timely filed from the mailing date of this of ONED (35 U.S.C. § 133).	·				
Status									
1)	Responsive to communication(s) filed o	n							
/	•		n is non-final.						
′=	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4\⊠	4)⊠ Claim(s) <u>1-35</u> is/are pending in the application.								
•	4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
	Claim(s) <u>1-6 and 17-20</u> is/are rejected.								
· · · · · · · · · · · · · · · · · · ·	Claim(s) <u>7-16 and 21-35</u> is/are objected to.								
8)[	8) Claim(s) are subject to restriction and/or election requirement.								
Application	on Papers								
	•	vaminer							
9)⊠ The specification is objected to by the Examiner.  10)⊠ The drawing(s) filed on <u>2December2003</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	nder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
	application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
Attachmo-	vie).								
Attachment	e of References Cited (PTO-892)		4) Interview Sumr	mary (PTO-413)					
2) Notice	e of Draftsperson's Patent Drawing Review (PTO-	948)	Paper No(s)/M	ail Date					
	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>1/04</u> .		5) Notice of Inform 6) Other:	nal Patent Application					

Application/Control Number: 10/727,017 Page 2

Art Unit: 1645

#### **DETAILED ACTION**

1. Claims 1-35 are pending. Claims 7-16 and 21-35 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, claims 7-16 and 21-35 have not been further treated on the merits.

2. Claims 1-6 and 17-20 are under consideration.

### **Priority**

3. The priority statement at the beginning of the specification must be amended to indicate the current status of all priority applications.

## **Specification**

4. The disclosure is objected to because of the following informalities:

Page 18, line 24, "procedures include" should be either "procedures which include" or "procedures including".

Appropriate correction is required.

# Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 1-6 and 17-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1645

The claims are drawn to a composition comprising lipid-based vehicles which comprise conjugates of the formula: A—(BC). B is a moiety comprising an internalizing peptide. C is a moiety comprising a biologically active agent. A is not defined concerning structure or function. The only restrictions on A appear to be that: A is a component conjugated to (BC) and appears to comprise a lipid (claim 2 and 6). Therefore, it is unclear what are the metes and bounds of component A.

#### Conclusion

- 7. No claims are allowed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's acting supervisor, Albert M. Navarro, can be reached on (571)272-0861.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1645

Page 4

RODNEY P SWARTZ, PH.C PRIMARY EXAMINER Art Unit 1645

September 30, 2006